Journal article

Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma

Olfat Kamel Hasan, Aravind S Ravi Kumar, Grace Kong, Kira Oleinikov, Simona Ben-Haim, Simona Grozinsky-Glasberg, Rodney J Hicks

Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2020


Esthesioneuroblastoma is rare, with limited therapeutic options when unresectable or metastatic; however, expression of somatostatin receptors qualifies it for peptide receptor radionuclide therapy (PRRT). We report outcomes of PRRT in esthesioneuroblastoma from 2 referral centers. Methods: Using PRRT databases at 2 European Neuroendocrine Tumor Society Centers of Excellence, cases were sought between 2004 and 2018 of patients who had PRRT with recurrent or metastatic esthesioneuroblastoma deemed unsuitable for further conventional therapies. Evaluations of survival and of response using a composite reference standard were performed. Results: Of 7 patients, 4 had partial response, 2 had dise..

View full abstract